Prospects for pharmacotherapy of schizophrenia

The Lancet

Volumn 345, Issue 8949, 1995, Pages 557-562

  Pickar, D ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

AGRANULOCYTOSIS; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEIZURE;

EID: 0028919572     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)90469-7     Document Type: Article

References (59)

1. One month prevalence of mental disorders in the US: based on five epidemiologic catchment area (ECA) sites
2. Schizophrenia, a high risk factor for suicide: clues to risk reduction
3. Treatment of schizophrenia
4. Schizophrenia an economic perspective
5. The costs of schizophrenia: assessing the burden
6. NIMH longitudinal study of chronic schizophrenia: prognosis and predictors of outcome
7. Dopamine receptor binding predicts clinical and pharmacologic potencies and antischizophrenic drugs
8. Antipsychotic drug doses and neuroleptic/dopamine receptors
9. Dopamine in schizophrenia: a review and reconceptualization
10. The current status of the dopamine hypothesis of schizophrenia
11. CSF and plasma monoamine metabolites and their relation to psychosis: implications for regional brain dysfunction in schizophrenia
12. Perspective on time-dependent model of neuroleptic action
13. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients
14. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: correlation with psychosis and response to neuroleptic treatment
15. Clozapine for the treatment-resistant schizophrenic a double-blind placebo comparison with chlorpromazine
16. Clinical and biological respone to clozapine in patients with schizophrenia: crossover comparison with fluphenazine
17. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia
18. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
19. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia
20. The effects of clozapine on tardive dyskinesia
21. Does clozapine cause tardive dyskinesia?
22. Suppression of dyskinesias in advanced Parkinson's disease: II. increasing daily clozapine doses suppress dyskinesias and improve Parkinsonism symptoms
23. Pharmacology of risperidone (R64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonist properties.
24. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
25. Risperidone in the treatment of schizophrenia
26. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons
27. Effect of clozapine on human serum prolactin levels
28. Antagonism of neurotransmitter receptors of normal human brain in vitro
29. Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic and histamine receptors to clinical potency
30. 4 receptor with high affinity for the antipsychotic clozapine
31. 4
32. Regionally specific effects of atypical antipsychotic drugs on striatal FOS expression: the nucleus accumbens shell as a locus of antipsychotic action
33. 1 values
34. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine 6 and 5-hydroxytryptamine-7 receptors
35. Gutierrez-Esteinou R, Hsiao J, et al. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia
36. 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study
37. In vitro and in vivo receptor binding effects on monoamine turnover in rat brain region of the novel antipsychotics risperidone and ocapieridone
38. Clinical profile of remoxipride—a combined analysis of comparative double blind multicentre trial programme
39. 2 dopamine receptor binding in the living human brain by PET
40. 2 dopamine receptors
41. 2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
42. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects
43. Dopamine receptor occupancy and plasma haloperidol levels
44. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia
45. Clozapine, single photon emission tomography and the D2 dopamine receptor blockade hypothesis of schizophrenia
46. The pharmacology of olanzapine and othe rnew antipsychotic agents
47. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound
48. 2 antagonist activities
49. Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia
50. Postpubertal emergence of hyperresponsiveness to stress and to amphohetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia.
51. Schizophrenia: a neurodevelopmental perspective
52. Schizophrenia a neurodevelopmental disorder: a review of the concept
53. 4 dopamine receptor (DRD4) gene does not predict response to clozapine in schizophrenic and schizoaffective subjects
54. Long-term action of lithium a role for transcriptional and post-transcriptional factors regulating protein kinase C